170 related articles for article (PubMed ID: 22956222)
1. [Immunosuppression in inflammatory bowel disease: When, how and how long?].
Gross V
Dtsch Med Wochenschr; 2012 Sep; 137(37):1803-5. PubMed ID: 22956222
[TBL] [Abstract][Full Text] [Related]
2. [Biological therapy as treatment of inflammatory bowel diseases].
Agnholt J
Ugeskr Laeger; 2008 Jun; 170(24):2152-6. PubMed ID: 18565302
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppression in inflammatory bowel disease: traditional, biological or both?
Van Assche G; Vermeire S; Rutgeerts P
Curr Opin Gastroenterol; 2009 Jul; 25(4):323-8. PubMed ID: 19417645
[TBL] [Abstract][Full Text] [Related]
4. [Cyclosporin A therapy in steroid-refractory patients with chronic inflammatory bowel diseases].
Dejaco C; Gasché C; Reinisch W; Moser G; Novacek G; Tillinger W; Vogelsang H; Gangl A
Wien Klin Wochenschr; 1998 Sep; 110(16):579-84. PubMed ID: 9782579
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of chronic inflammatory bowel disease based on evidence and according to stage: top down].
Mudter J; Neurath MF
Dtsch Med Wochenschr; 2013 Sep; 138(36):1779. PubMed ID: 24002879
[No Abstract] [Full Text] [Related]
6. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
Trinder MW; Lawrance IC
J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
[TBL] [Abstract][Full Text] [Related]
7. [Chronic inflammatory bowel diseases. Earlier transition to immunosuppressive drugs].
Bischoff A
MMW Fortschr Med; 2002 May; 144(18):10. PubMed ID: 12422699
[No Abstract] [Full Text] [Related]
8. Therapy of steroid-resistant inflammatory bowel disease.
Manz M; Vavricka SR; Wanner R; Lakatos PL; Rogler G; Frei P; Safroneeva E; Schoepfer AM
Digestion; 2012; 86 Suppl 1():11-5. PubMed ID: 23051721
[TBL] [Abstract][Full Text] [Related]
9. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
10. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506).
Fellermann K; Ludwig D; Stahl M; David-Walek T; Stange EF
Am J Gastroenterol; 1998 Oct; 93(10):1860-6. PubMed ID: 9772045
[TBL] [Abstract][Full Text] [Related]
11. Vaccinating patients with inflammatory bowel disease--primum non nocere.
Muhammad R; Wong CL; Limdi JK
Scand J Gastroenterol; 2012 Sep; 47(8-9):1122-3. PubMed ID: 22554229
[No Abstract] [Full Text] [Related]
12. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up.
Baumgart DC; Pintoffl JP; Sturm A; Wiedenmann B; Dignass AU
Am J Gastroenterol; 2006 May; 101(5):1048-56. PubMed ID: 16573777
[TBL] [Abstract][Full Text] [Related]
13. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy.
Oussalah A; Chevaux JB; Fay R; Sandborn WJ; Bigard MA; Peyrin-Biroulet L
Am J Gastroenterol; 2010 May; 105(5):1142-9. PubMed ID: 20389296
[TBL] [Abstract][Full Text] [Related]
14. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
15. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
Roblin X; Serre-Debeauvais F; Phelip JM; Faucheron JL; Hardy G; Chartier A; Helluwaert F; Bessard G; Bonaz B
Aliment Pharmacol Ther; 2005 Apr; 21(7):829-39. PubMed ID: 15801918
[TBL] [Abstract][Full Text] [Related]
16. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease.
Orlando A; Armuzzi A; Papi C; Annese V; Ardizzone S; Biancone L; Bortoli A; Castiglione F; D'Incà R; Gionchetti P; Kohn A; Poggioli G; Rizzello F; Vecchi M; Cottone M; ;
Dig Liver Dis; 2011 Jan; 43(1):1-20. PubMed ID: 20843756
[TBL] [Abstract][Full Text] [Related]
17. [Adalimumab for the treatment of Crohn's disease - consensus paper of the Working Group "chronic inflammatory bowel diseases" of the Austrian Society for Gastroenterology and Hepatology].
Reinisch W; Haas T; Kaser A; Petritsch W; Vogelsang H; Feichtenschlager T; Novacek G; Siebert F; Tilg H; Knoflach P
Z Gastroenterol; 2009 Apr; 47(4):372-80. PubMed ID: 19358065
[TBL] [Abstract][Full Text] [Related]
18. [Biological drugs in inflammatory bowel disease. Valuable supplement--but only when conventional therapy is not sufficient].
Hellström PM; Schmidt D; Karlén P
Lakartidningen; 2007 Oct 10-16; 104(41):2973-6. PubMed ID: 17977308
[No Abstract] [Full Text] [Related]
19. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections.
Schneeweiss S; Korzenik J; Solomon DH; Canning C; Lee J; Bressler B
Aliment Pharmacol Ther; 2009 Aug; 30(3):253-64. PubMed ID: 19438424
[TBL] [Abstract][Full Text] [Related]
20. [Chronic inflammatory bowel diseases. No fear with powerful preventive drugs].
Rautenstrauch J
MMW Fortschr Med; 2000 Nov; 142(45):18. PubMed ID: 11107819
[No Abstract] [Full Text] [Related]
[Next] [New Search]
